Publication: Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
Issued Date
2011-01-01
Resource Type
ISSN
15928721
03906078
03906078
Other identifier(s)
2-s2.0-78650996705
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Haematologica. Vol.96, No.1 (2011), 48-54
Suggested Citation
Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. Vol.96, No.1 (2011), 48-54. doi:10.3324/haematol.2010.031468 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12780
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
Other Contributor(s)
Royal Brompton Hospital
UCL
Universita degli Studi di Milano
University of Malaya Medical Centre
Cairo University
Ege University Medical School
Kuala Lumpur Hospital
Prince of Wales Hospital Hong Kong
Mahidol University
Ain Shams University
University of Athens
Novartis Pharmaceuticals
Novartis International AG
American University of Beirut
UCL
Universita degli Studi di Milano
University of Malaya Medical Centre
Cairo University
Ege University Medical School
Kuala Lumpur Hospital
Prince of Wales Hospital Hong Kong
Mahidol University
Ain Shams University
University of Athens
Novartis Pharmaceuticals
Novartis International AG
American University of Beirut
Abstract
Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial. Design and Methods Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years. Results Baseline myocardial T2* was severe ( > 5 to < 10 ms) in 39 patients, and moderate-to-mild (10 to < 20 ms) in 62 patients. Mean deferasirox dose was 33.1±3.7 mg/kg/d in the one-year core study increasing to 36.1±7.7 mg/kg/d during the second year of treatment. Geometric mean myocardial T2* increased from a baseline of 11.2 to 14.8 ms at two years (P < 0.001). In patients with moderate-to-mild baseline T2*, an increase was seen from 14.7 to 20.1 ms, with normalization (≥20 ms) in 56.7% of patients. In those with severe cardiac iron overload at baseline, 42.9% improved to the moderate-to-mild group. The incidence of drug-related adverse events did not increase during the extension relative to the core study and included (≥5%) increased serum creatinine, rash and increased alanine aminotransferase. Conclusions Continuous treatment with deferasirox for two years with a target dose of 40 mg/kg/d continued to remove iron from the heart in patients with β-thalassemia major and mild, moderate and severe cardiac siderosis. © 2011 Ferrata Storti Foundation.